Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in Ambulatory Patients With Mild COVID-19
NCT04361214Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- May 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in coronavirus disease 2019 (COVID-19), sponsored by University of Chicago. Primary endpoints: Tolerability of high dose leflunomide as measured by leflunomide dose modifications at 14 days, Tolerability of high dose leflunomide as measured by discontinuation of leflunomide at 14 days and 1 more. Started May 2020; status: terminated.
02
Drugs
leflunomide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04361214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361214.